2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
18
Prostatic Neoplasms
11
Carcinoma, Hepatocellular
8
Liver Neoplasms
7
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Squamous Intraepithelial Lesions
2
Neoplasms
2
Lymphatic Metastasis
2
Locally Advanced Pancreatic Cancer
2
Kidney Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Carboplatin
72
Docetaxel
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
42
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Electroporation
×
Clear all
NCT02430701
2021-09-05
IRE
Fuda Cancer Hospital, Guangzhou
Phase NA
Completed
30 enrolled